[{"orgOrder":0,"company":"IOVaxis Therapeutics","sponsor":"Targovax","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"TG01","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"IOVaxis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"IOVaxis Therapeutics \/ IOVaxis","highestDevelopmentStatusID":"5","companyTruncated":"IOVaxis Therapeutics \/ IOVaxis"}]

Find Clinical Drug Pipeline Developments & Deals by IOVaxis Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Targovax has granted an extension of 3 months to the exclusive option agreement with IOVaxis Therapeutics of Nantong, China, for clinical development and licensing of the Targovax mutant RAS vaccines TG01 and TG02 in China, Hong Kong, Macau and Singapore...

                          Brand Name : TG01

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          January 06, 2021

                          Lead Product(s) : Apricoxib

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Recipient : Targovax

                          Deal Size : $3.0 million

                          Deal Type : Licensing Agreement

                          blank